HealthEquity (NASDAQ:HQY) Receives Outperform Rating from Barrington Research

Barrington Research reissued their outperform rating on shares of HealthEquity (NASDAQ:HQY) in a research report released on Thursday,Benzinga reports. Barrington Research currently has a $125.00 price target on the stock.

A number of other equities research analysts have also weighed in on the stock. Jefferies Financial Group boosted their target price on shares of HealthEquity from $130.00 to $134.00 and gave the stock a “buy” rating in a report on Wednesday, September 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of HealthEquity in a research note on Wednesday, October 8th. Citizens Jmp increased their price objective on HealthEquity from $117.00 to $122.00 and gave the company a “market outperform” rating in a report on Thursday. Citigroup reaffirmed an “outperform” rating on shares of HealthEquity in a report on Thursday. Finally, JMP Securities set a $122.00 price target on HealthEquity in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $120.07.

HealthEquity Price Performance

Shares of HQY opened at $95.67 on Thursday. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.47. The stock has a market cap of $8.24 billion, a PE ratio of 43.89, a PEG ratio of 1.42 and a beta of 0.18. HealthEquity has a 12-month low of $74.07 and a 12-month high of $116.65. The business has a 50-day simple moving average of $96.41 and a two-hundred day simple moving average of $96.87.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Wednesday, December 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. HealthEquity had a return on equity of 12.95% and a net margin of 14.86%.The company had revenue of $322.16 million for the quarter, compared to analysts’ expectations of $320.92 million. During the same period in the previous year, the business posted $0.78 earnings per share. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS. Analysts anticipate that HealthEquity will post 2.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other HealthEquity news, EVP Michael Henry Fiore sold 1,781 shares of the stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $88.21, for a total transaction of $157,102.01. Following the completion of the sale, the executive vice president directly owned 49,795 shares in the company, valued at approximately $4,392,416.95. This trade represents a 3.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Delano Ladd sold 1,500 shares of HealthEquity stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $104.56, for a total value of $156,840.00. Following the completion of the transaction, the executive vice president directly owned 75,479 shares of the company’s stock, valued at approximately $7,892,084.24. This trade represents a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,781 shares of company stock worth $1,016,707 in the last ninety days. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On HealthEquity

Institutional investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers grew its position in shares of HealthEquity by 47.3% during the 1st quarter. Cetera Investment Advisers now owns 5,260 shares of the company’s stock worth $465,000 after buying an additional 1,688 shares during the period. Federated Hermes Inc. lifted its position in shares of HealthEquity by 18.8% during the 1st quarter. Federated Hermes Inc. now owns 9,756 shares of the company’s stock valued at $862,000 after acquiring an additional 1,547 shares during the period. US Bancorp DE boosted its stake in HealthEquity by 1.3% during the first quarter. US Bancorp DE now owns 18,350 shares of the company’s stock worth $1,622,000 after acquiring an additional 244 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in HealthEquity by 47.1% in the first quarter. PNC Financial Services Group Inc. now owns 13,063 shares of the company’s stock worth $1,154,000 after purchasing an additional 4,183 shares during the period. Finally, New Age Alpha Advisors LLC grew its holdings in HealthEquity by 755.8% in the first quarter. New Age Alpha Advisors LLC now owns 22,175 shares of the company’s stock worth $1,960,000 after purchasing an additional 19,584 shares during the period. 99.55% of the stock is owned by institutional investors and hedge funds.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.